|
1. |
Further evidence of the need to establish treatment safety as well as efficacy in randomized controlled trials |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 591-593
Andrew Tonkin,
Carlos Dujovne,
Preview
|
PDF (50KB)
|
|
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
2. |
Measurement of subclinical atherosclerosis: beyond risk factor assessment |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 595-603
Radjesh Bisoendial,
G. Kees Hovingh,
Eric de Groot,
John Kastelein,
Peter Lansberg,
Erik Stroes,
Preview
|
PDF (183KB)
|
|
摘要:
Purpose of reviewAssessment of subclinical atherosclerosis using the current available noninvasive imaging modalities holds promise for individual cardiovascular risk management and monitoring efficacy of therapeutic interventions (i.e. surrogate end-points). The present review addresses benefits and limitations of flow-mediated dilatation, intima-media thickness, electron-beam computed tomography and magnetic resonance coronary angiography.Recent findingsBoth carotid intima-media thickness and peripheral flow-mediated dilatation correlate inversely with cardiovascular risk factors and coronary artery disease. They have been shown to carry predictive value for future cardiovascular events, but clinical application of both intima-media thickness and flow-mediated dilatation demands further methodological maturation of these techniques. Intima thickening has been successfully targeted in numerous intervention trials, but determination of an explicit threshold value beyond which cardiovascular risk significantly increases will facilitate its utility as a routine clinical tool. Electron-beam computed tomography can accurately detect and quantify coronary artery calcification (an established marker of the total coronary plaque burden). However, lack of evidence of its additional predictive power for future coronary events warrants for further research. Finally, magnetic resonance coronary angiography appears to be a promising technique, integrating both functional and anatomical aspects of coronary artery disease. Properly designed studies are needed to determine its value in clinical practice.SummaryVarious noninvasive imaging techniques have recently emerged that may find applications in clinical research. However, before widespread clinical utilization, further technical refinement of all of the cited imaging modalities is mandatory. It will be a challenge over the coming few years to clarify whether improvements in surrogate end-points can directly be translated into improved outcomes.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
3. |
HDL and triglyceride as therapeutic targets |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 605-616
Jean-Charles Fruchart,
Patrick Duriez,
Preview
|
PDF (122KB)
|
|
摘要:
Purpose of ReviewEpidemiological studies have shown that plasma HDL-cholesterol is inversely related to coronary artery disease and that there is an inverse relationship between HDL-cholesterol and triglyceride levels, but it is now demonstrated that hypertriglyceridemia is an independent risk factor for coronary heart disease (CHD). The goal of this review is to discuss if triglycerides and HDL-cholesterol could be therapeutic targets to reduce cardiovascular risk.Recent findingsTriglyceride measurement is not informative on the specificity of the triglyceride-rich lipoproteins present in the plasma because some of these are not atherogenic (chylomicrons, large VLDLs) while others are highly atherogenic (small VLDLs, remnants, IDL...). Statins, in addition to reducing LDL-cholesterol, significantly reduced atherogenic remnant lipoprotein cholesterol levels. 4S, CARE+LIPID, and AFCAPS/TexCAPS studies, suggested enhanced therapeutic potential of statins for improving triglyceride and HDL-cholesterol levels in patients with CHD. A fibrate (gemfibrozil) was shown to reduce death from CHD and non-fatal myocardial infarction in secondary prevention of CHD in men with low levels of HDL-cholesterol (VA-HIT); during the treatment these levels predicted the magnitude of reduction in risk for CHD events.SummaryATP III recommendations state, on triglycerides and HDL-cholesterol as targets to reduce cardiovascular risk: (1) that lowering LDL-cholesterol levels is the primary target of therapy, (2) a secondary target is to achieve a triglyceride level <150 mg/dL and (3) clinical trial data are considered to be insufficient to support recommanded a specific HDL-cholesterol goal even if HDL-cholesterol <40 mg/dL is considered to be a major risk factor of CHD.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
4. |
Lipid-lowering therapy in people with type 2 diabetes |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 617-623
Stephen Colagiuri,
James Best,
Preview
|
PDF (81KB)
|
|
摘要:
Purpose of reviewThe risk of cardiovascular disease is markedly increased in people with type 2 diabetes. There is abundant epidemiological and clinical trial evidence that lipid abnormalities play a major role in the pathogenesis of atherosclerotic vascular disease in diabetes. Although the benefits of lipid-lowering therapy are well established in people without diabetes, the evidence in people with diabetes is not as well established.Recent findingsRecent population studies of lipid-lowering therapy and cardiovascular disease outcomes that included people with diabetes and performed a separate subgroup analysis were reviewed. Lipid lowering with statins and fibrates is effective in improving cardiovascular disease outcomes in diabetes, and their effectiveness is similar to that in the non-diabetic population. This effect is well established in secondary prevention and is accumulating for primary prevention.SummaryIndividuals with diabetes require aggressive management of dyslipidaemia as part of an overall management strategy to reduce the risk of cardiovascular disease. Individuals with a previous cardiovascular disease event should be on lipid-lowering therapy, whereas in those who have not had a previous cardiovascular disease event, the decision to use lipid-lowering therapy should be based on lipid levels and the overall risk of a future event. The results of large studies that are currently in progress specifically in people with diabetes should resolve outstanding questions in relation to lipid-lowering therapy in diabetes.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
5. |
Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 625-630
Robert Rosenson,
Alan Brown,
Preview
|
PDF (82KB)
|
|
摘要:
Purpose of reviewReview the cellular mechanisms and clinical evidence for the use of statins in patients with unstable coronary syndromes.Recent findingsClinical trials of statin therapy in acute coronary syndromes demonstrate a rapid improvement in endothelial function, improved perfusion to ischemic myocardium, and an early reduction in cardiovascular events. The early benefit of statin therapy is related to a combination of molecular mechanisms that involve the oxidized LDL receptor (LOX-1), endothelial localized nitric oxide synthase, inflammatory cytokines, interstitial collagenases, and tissue factor expression. In human atheroma, 3 months' use of statin (pravastatin) therapy reduced the content of oxidized LDL, inflammatory cells (macrophage, T cells) infiltrates, and improved plaque stability by increasing the collagen content of the fibrous cap.SummaryThe antiatherothrombotic effects of statin therapy appear to have important clinical relevance to patients with impaired myocardial perfusion and acute coronary syndrome.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
6. |
Early initiation of statin therapy after a coronary event |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 631-635
Barry McKeown,
Peter Thompson,
Preview
|
PDF (74KB)
|
|
摘要:
Purpose of reviewDespite improvements in the early management of acute coronary syndromes, the risk of major cardiovascular complications remains high. Lipid-modifying treatment with statins has the potential to further improve outcomes through improved endothelial function, antithrombotic and antiinflammatory actions. Statins are of proven benefit in patients with stable coronary heart disease. There has been speculation on potential mechanisms of benefit but, until recently, little data on the efficacy and safety of statins in the acute setting. Recent observational studies and randomized trials have addressed some of the questions regarding early initiation of statins in acute coronary syndromes.Recent findingsRecent observational and randomized trials have shown that early commencement of statins in acute coronary syndromes is safe as early as 6 hours after the event and is likely to improve longer-term compliance. The current data are not sufficient to draw conclusions about the efficacy of statins early in the course of acute coronary syndromes.SummaryCurrent management for acute coronary syndromes should include the commencement of statin therapy during initial hospital admission. This recommendation is based on safety and compliance data. More randomized trial evidence is required to determine whether early initiation will produce better outcomes than later initiation after an acute coronary event.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
7. |
Safety considerations for statins |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 637-644
Chiara Bolego,
Roberta Baetta,
Stefano Bellosta,
Alberto Corsini,
Rodolfo Paoletti,
Preview
|
PDF (90KB)
|
|
摘要:
Purpose of reviewThe hydroxymethyl glutaryl coenzyme A reductase inhibitors or statins offer important benefits for the large populations of individuals at high risk for coronary heart disease. These drugs have a good safety profile. Nevertheless, differences in physicochemical and pharmacokinetic properties between statins may translate into significant differences in long-term safety. This review focuses on long-term adverse effects related to statin use, namely hepatotoxicity and myopathy. Moreover, the most common drugs used in combination with statins in long-term therapies are analyzed in terms of possible drug/drug interactions affecting the safety of statins.Recent findingsThe withdrawal of cerivastatin from the global market in 2001, because of severe cases of rhabdomyolysis, highlighted concerns regarding the safety of the entire class. Afterwards, the role of statins and their interactions with other drugs in precipitating this condition have been carefully reviewed. In approximately 60% of the total number of cases, statin-related rhabdomyolysis was found to be related to drug/drug interactions. Recently, all cases of fatal rhabdomyolysis associated with statin use have been reported to the US Food and Drug Administration. This has shown that fatal rhabdomyolysis among statin users is a rare event, the reporting rates being much less than one death per million prescriptions in the case of all statins except cerivastatin.SummaryThe safety and tolerability of the available statins support their use as the first-line treatment of patients at high risk for coronary heart disease, since the clinical benefits greatly outweigh the small risk of myopathy. Nevertheless, clinicians should be aware of the adverse effects possibly related to statin therapy, particularly in patients at high risk for coronary heart disease and requiring long-term multiple-drug therapies.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
8. |
Role of lipid-modifying therapy in the prevention of initial and recurrent stroke |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 645-651
Graeme Hankey,
Preview
|
PDF (85KB)
|
|
摘要:
Purpose of reviewTo establish the role of cholesterol-modifying therapy in stroke prevention.Recent findingsPopulation-based observational cohort studies show a variable weak positive relationship between increasing plasma total cholesterol concentrations and an increasing risk of ischaemic stroke, which is partly offset by a weaker negative association between decreasing total cholesterol concentrations and an increasing risk of with haemorrhagic stroke. However, randomized controlled trials show unequivocally that lowering plasma total cholesterol by approximately 1.2 mmol/l (and LDL-cholesterol by 1.0 mmol/l) is associated with a reduced relative risk of stroke and other serious vascular events by at least a quarter, and probably a third, without any increase in haemorrhagic stroke, in a wide range of men and women (including individuals with previous stroke). The proportional reduction in stroke risk is consistent, irrespective of the patient's age, baseline plasma cholesterol concentration, and absolute risk of stroke (although perhaps less in very low-risk individuals), but is increased with greater degrees of cholesterol lowering (15% or more), and thus with statin medications, which are more potent than non-statin interventions in lowering cholesterol levels. The absolute reduction in stroke risk achieved by statins is greatest among individuals at highest risk of stroke. Preliminary evidence suggests that lowering total cholesterol levels by diet may be an effective adjunctive therapy to statins, and raising plasma HDL-cholesterol concentrations among patients with coronary heart disease and low HDL-cholesterol levels ( 1 mmol/l) by means of gemfibrozil may also effectively prevent stroke.SummaryStatin drugs are effective and safe in preventing initial and recurrent stroke. However, because they are costly, they should probably be restricted to individuals with an annual risk of stroke and other serious vascular events of 3% or greater, and possibly as low as 1.5%, because routine monitoring of plasma cholesterol, and liver and muscle enzyme concentrations is probably no longer necessary.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
9. |
Clinical trials of gene therapy for atherosclerotic cardiovascular disease |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 653-661
Saul Freedman,
Preview
|
PDF (106KB)
|
|
摘要:
Purpose of reviewTo provide an update on clinical trials of gene therapy for atherosclerotic cardiovascular disease published since 1 August 2001 and summarize the general advantages and potential problems of gene transfer in these disorders.Recent findingsThere are two major areas in which gene therapy has entered clinical trials. The first is angiogenesis for coronary and peripheral arterial disease. Two relatively small placebo-controlled trials for coronary disease were reported, one using intramyocardial plasmidVEGF-2gene, the other using intracoronary adenoviralFGF-4gene. TheVEGF-2study in no-option patients showed reduced angina, and significant improvement in perfusion and function, whereas theFGF-4study in less severely affected patients showed promising results in some subsets. In peripheral artery disease two phase 1 studies of adenoviralNV1FGFandVEGFshowed some objective improvement in pain, ulcer size and ankle : brachial index in one study and endothelial function in the other. Both adenoviral and plasmidVEGFgene transfer at angioplasty increased vascularity in a phase 2 double-blind study. The other major area is the prevention of graft disease and restenosis using antisense oligodeoxynucleotides. E2F decoy led to a significant reduction in venous graft complications after ex-vivo transfection at the time of coronary bypass surgery, whereas the c-Myc oligodeoxynucleotide was ineffective in preventing in-stent coronary restenosis.SummaryThere are more reviews of gene therapy for atherosclerosis in the literature than publications with original data or trials, but in the past year the imbalance is being redressed, with some promising results from controlled studies.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
10. |
The future direction of cholesterol-lowering therapy |
|
Current Opinion in Lipidology,
Volume 13,
Issue 6,
2002,
Page 663-669
Marc Evans,
Aled Roberts,
Alan Rees,
Preview
|
PDF (83KB)
|
|
摘要:
Purpose of reviewObservational studies suggest a continuous positive relationship between vascular risk and cholesterol without any lower threshold level. We review recent and future clinical trials addressing the question of optimal treatment goals for cholesterol reduction and how these relate to present guidelines. With increasing focus on greater cholesterol reduction, new approaches to lipid-lowering therapy are being developed; we discuss some of these agents including the new statin, rosuvastatin and novel cholesterol transport inhibitors such as ezetimibe.Recent findingsThe Heart Protection Study demonstrated that LDL cholesterol reduction to levels as low as 1.7 mmol/l was associated with significant clinical benefit in a wide range of high-risk individuals, irrespective of baseline cholesterol levels, with no apparent threshold level for LDL cholesterol with respect to cardiovascular risk. The Heart Protection Study also demonstrated that the benefits of LDL cholesterol reduction extend into peripheral vascular disease and cerebrovascular disease prevention and suggest that the most recent National Cholesterol Education Program Adult Treatment Panel III guidelines, with LDL cholesterol targets of 2.6 mmol/l, may result in undertreatment of a large number of patients. Various large end-point trials, including Treating to New Targets and Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine will attempt to further address the issue of optimal LDL cholesterol reduction. New therapies are being developed to meet the challenge of more intensive cholesterol lowering. Rosuvastatin is a potent, hydrophilic enantiomeric statin producing reductions in LDL cholesterol of 40-69% over its dose range of 5-80 mg. Ezetimibe is a selective cholesterol absorption inhibitor, with a site of action at the intestinal epithelium. Optimum reductions in LDL cholesterol of up to 25 and 60% reduction in chylomicron cholesterol content are seen with a 10-mg dose.SummaryEvidence is accumulating supporting the safety and benefits of aggressive cholesterol reduction, with no apparent threshold for LDL cholesterol. New therapies will aid in achieving lower cholesterol levels and the use of combination therapies targeting different aspects of cholesterol metabolism may produce additional benefits. Outcome studies are awaited to further address these issues.
ISSN:0957-9672
出版商:OVID
年代:2002
数据来源: OVID
|
|